enGene Holdings Inc. Common Stock (ENGN NASDAQ) stock market data APIs
$4.7913
0.03(0.6%)
as of April 23, 2025
enGene Holdings Inc. Common Stock Financial Data Overview
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.
Prev. Close
4.7913
Open
4.8189
High
4.8517
Low
4.7607
52 wk Range
3.8022-16.6189
Market Cap
203 M
Shares Outstanding
50 978 K
EPS
-0.48
Beta
-0.37
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get enGene Holdings Inc. Common Stock data using free add-ons & libraries
Get enGene Holdings Inc. Common Stock Fundamental Data
enGene Holdings Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -78 024 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-11
- EPS/Forecast: -0.3783
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
enGene Holdings Inc. Common Stock News
New
Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now?
We recently published a list of 13 Best Canadian Penny Stocks to Invest in Now In this article, we are going to take a look at where enGene Holdings Inc. (NASDAQ:ENGN) stands against other best Canadi...
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage...
Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023
Round co-led by Forbion and EQT Life Sciences Financing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS) and additional pip...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
